Controversies in testosterone supplementation therapy.

Abstract

Testosterone has now become one of the most widely used medications throughout the world. The rapid growth of the testosterone market in the past 10 years is due to many factors. We currently have a worldwide aging population. In the US, the number of men 65 years old or older is increasing 2-3 times faster than the number of men younger than 65 years. In addition, poor general health and certain medical conditions such as diabetes/metabolic syndrome (MetS), cardiovascular disease (CVD), and osteoporosis have been associated with low serum testosterone levels. [1],[2],[3] There are now fewer concerns regarding the development of prostate cancer (PCa) after testosterone therapy, making it a more attractive treatment option. Finally, the introduction of different forms of testosterone supplementation therapy (TST) with increased promotion, marketing, and direct-to-consumer advertising is also driving market growth. As the demand for TST continues to grow, it is becoming more important for clinicians to understand how to diagnose and treat patients with low testosterone.

• Authors: Mohit Khera
• Journal: Asian journal of andrology (Asian J Androl) 2015 Mar-Apr Vol. 17 Issue 2 Pg. 175-6 ISSN: 1745-7262 [Electronic] China
• PMID: 25652639 (Publication Type: Journal Article)

Chemical References

• Testosterone

Topics

• Aged
• Aged, 80 and over
• Aging (metabolism)
• Cardiovascular Diseases (complications, metabolism)
• Diabetes Complications (complications, metabolism)
• Eunuchism (drug therapy, metabolism)
• Hormone Replacement Therapy
• Humans
• Lower Urinary Tract Symptoms (epidemiology)
• Male
• Osteoporosis (complications, metabolism)
• Prostatic Hyperplasia (epidemiology)
• Prostatic Neoplasms (epidemiology)
• Risk Factors
• Testosterone (adverse effects, deficiency, therapeutic use)